Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche/AbbVie Move Beyond GDC-0199 Toxicity Issue To Show Results In Tough-To-Treat CLL

This article was originally published in The Pink Sheet Daily

Executive Summary

Small molecule Bcl-2 inhibitor GDC-0199/ABT-199 demonstrates an 84% overall response rate and a 23% complete response in early study of high risk CLL presented at ASH. However, tumor lysis syndrome caused one sudden death in the trial and is a potential risk that needs to be well-managed going forward. Roche also reports updated results of Gazyva vs. Rituxan in CLL.

You may also be interested in...

FDA Accentuates Venclexta Superiority To Imbruvica

FDA denied breakthrough therapy request until AbbVie and Roche demonstrated substantial improvement over available treatment in 17p deletion chronic lymphocytic leukemia, review documents show.

Venclexta Out Of The Starting Gate With Approval In High-Risk CLL Subset

Roche/Abbvie’s first-in-class breakthrough BCL-2 inhibitor granted accelerated approval by FDA in relapsed CLL with 17p deletion.

Breast Cancer Protection Plan In Place, Roche Turns Attention To Hematology

With new drugs at hand to protect its Herceptin breast cancer franchise, Roche announced positive data for its rituximab replacement candidate and other steps in its plan to protect top-seller Rituxan/MabThera.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts